Cirrhosis Market and Pipeline Insights, 2024: Analysis of Emerging Drugs GXHPC 1 (GWOXI Stem Cell Applied Technology), LPCN 1148 (Lipocine), and Belapectin (Galectin Therapeutics)
11 avr. 2024 11h06 HE
|
Research and Markets
Dublin, April 11, 2024 (GLOBE NEWSWIRE) -- The "Cirrhosis - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.This report provides comprehensive insights...
Ocera Therapeutics Reports Second Quarter 2017 Financial Results
01 août 2017 16h05 HE
|
Ocera Therapeutics, Inc.
REDWOOD CITY, Calif. and RESEARCH TRIANGLE PARK, N.C., Aug. 01, 2017 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), a clinical stage biopharmaceutical company focused on the development...
Ocera Initiates Phase 2a Study with Oral OCR-002 in Patients with Cirrhosis
01 juin 2017 09h05 HE
|
Ocera Therapeutics, Inc.
REDWOOD CITY, Calif. and RESEARCH TRIANGLE PARK, N.C., June 01, 2017 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), today announced the dosing of the first patients in Part Two of a...
Ocera Therapeutics Highlights OCR-002 Data to be Presented at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
05 oct. 2015 16h05 HE
|
Ocera Therapeutics, Inc.
PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., Oct. 05, 2015 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), a clinical stage biopharmaceutical company focused on acute and...
Ocera Reports Pipeline Progress and First Quarter 2015 Financial Results
30 avr. 2015 08h05 HE
|
Ocera Therapeutics, Inc.
Strong Enrollment in STOP-HE Trial
Conference Call and Webcast at 10:00 a.m. ET
PALO ALTO, Calif., April 30, 2015 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (Nasdaq:OCRX), a clinical stage...
Ocera Therapeutics to Report Pipeline Progress and First Quarter 2015 Financial Results
22 avr. 2015 16h43 HE
|
Ocera Therapeutics, Inc.
PALO ALTO, Calif., April 22, 2015 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (Nasdaq:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today...
Ocera Reports Fourth Quarter and Full Year 2014 Financial Results
11 mars 2015 16h01 HE
|
Ocera Therapeutics, Inc.
PALO ALTO, Calif., March 11, 2015 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (Nasdaq:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today...
Ocera Therapeutics to Present at 13th Annual BIO Investor Forum
29 sept. 2014 09h00 HE
|
Ocera Therapeutics, Inc.
PALO ALTO, Calif., Sept. 29, 2014 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (Nasdaq:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today...
Ocera Therapeutics Raises $25.2 Million in Public Offering
10 juil. 2014 08h33 HE
|
Ocera Therapeutics, Inc.
PALO ALTO, Calif., July 10, 2014 (GLOBE NEWSWIRE) -- Ocera Therapeutics (Nasdaq:OCRX) ("Ocera") today announced that it has priced an underwritten public offering of 4,200,000 shares of its common...
Ocera Therapeutics Announces Proposed Public Offering of Common Stock
09 juil. 2014 16h01 HE
|
Ocera Therapeutics, Inc.
PALO ALTO, Calif., July 9, 2014 (GLOBE NEWSWIRE) -- Ocera Therapeutics (Nasdaq:OCRX) ("Ocera" or "the Company") today announced that it intends to offer and sell, subject to market and other...